GlassScriptPhysician profile
Vivek Ravindra Patel
NPI 1174604292
$80,532.24
in general payments reported to CMS, 2019-2025
13 companies · $5,997 in 2025
The $5,997 reported for 2025 was more than what 88% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $20K · 2021: $10K · 2022: $21K · 2023: $17K · 2024: $5,776 · 2025: $5,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Consulting Fee: $5,025 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,800 · Food and Beverage: $2,759 · Travel and Lodging: $1,550 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $14,212.50 |
| Consulting Fee | $5,025.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,800.00 |
| Food and Beverage | $2,759.17 |
| Travel and Lodging | $1,549.82 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $57,812.81 | 2019-2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $10,546.60 | 2020-2025 | Ultomiris, Soliris |
| Amgen INC. | $5,893.15 | 2024-2025 | Tepezza |
| Argenx US, INC. | $5,038.12 | 2025 | Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $333.15 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $324.66 | 2024-2025 | Artevo 800 |
| Alcon Vision LLC | $236.67 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $130.34 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $113.05 | 2021 | |
| Abbvie INC. | $32.75 | 2023 | |
| Ucb, INC. | $30.00 | 2025 | Rystiggo |
| Dompe US, INC. | $26.96 | 2024 | Oxervate |
| Integra Lifesciences Corporation | $13.98 | 2025 | Integra Duo, Instruments-Orthopedic, Codman Isocool Aht |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.